53312-82-6

Upstream product

• 36282-26-5 2-bromo-4-fluorobenzonitrile 
• 34662-35-6 2-bromo-4-nitrobenzonitrile 
• 13296-94-1 2-bromo-4-nitroaniline 
• 100-01-6 4-nitro-aniline 

Downstream Products

• 1008714-30-4 [1-(3-bromo-4-cyanophenyl)-2-oxo-2,4,5,6,7,7a-hexahydro-1H-indol-3-yl]-acetic acid 
• 1189353-62-5 2-bromo-4-(dimethylamino)benzonitrile 
• 1459140-41-0 1-(3-bromo-4-cyanophenyl)-3-(5-(pyridin-4-yl)-1,3,4-thiadiazol-2-yl)urea 
• 1261494-69-2 C₈H₃BrN₂O 

Relevant academic research and scientific papers

Structure-activity relationship of benzodiazepine derivatives as LXXLL peptide mimetics that inhibit the interaction of vitamin D receptor with coactivators

Suppression of vitamin D receptor (VDR)-mediated transcription is expected to be of therapeutic value in Paget's disease of bone. It is known that interaction between VDR and coactivators is necessary for VDR transactivation, and the interaction occurs wh

Concise synthesis of highly substituted benzo[a]quinolizines by a multicomponent reaction/allylation/heck reaction sequence

The combination of the recently developed multicomponent construction of highly substituted 3,4-dihydropyridones with subsequent allylation and intramolecular Heck-type cyclization allows the straightforward construction of benzo[a]quinolizines, a class of polycyclic compounds that- despite their interesting pharmacological and photochemical properties- have little precedent in the literature. After optimization of the individual steps, we used this reliable three-step sequence to generate a small library of diversely substituted benzo[a]quinolizines and various heterocyclic analogs. Copyright

FUSED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION

Disclosed are fused heterocyclic compounds of Formula (I) or pharmaceutically-acceptable salts or stereoisomers thereof. Also disclosed are methods of using such compounds in the treatment of at least one androgen receptor-associated condition, such as, for example, cancer, and pharmaceutical compositions comprising such compounds.

Benzene, Pyridine, and Pyridazine Derivatives

Disclosed are compounds and pharmaceutically acceptable salts of Formula I wherein A, Q1, Q2, Q3, R3, and R4 are as defined herein. Compounds of Formula I are useful in the treatment of diseases and/o